| Year |
Citation |
Score |
| 2019 |
Cao Y, Chang Q, Zhang W, Ornatsky O, Hedley D, Chen EX. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. Cancer Chemotherapy and Pharmacology. PMID 31520102 DOI: 10.1007/S00280-019-03956-6 |
0.329 |
|
| 2019 |
Connor AA, Denroche RE, Jang GH, Lemire M, Zhang A, Chan-Seng-Yue M, Wilson G, Grant RC, Merico D, Lungu I, Bartlett JMS, Chadwick D, Liang SB, Eagles J, Mbabaali F, ... ... Hedley D, et al. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell. PMID 30686769 DOI: 10.1016/J.Ccell.2018.12.010 |
0.394 |
|
| 2019 |
Jain P, Sayad A, Mollen E, Xie M, Brown K, Moffat J, Hedley D, Boutros P, Wouters B, Koritzinsky M. Abstract 883: PRDX4 as a novel target for pancreatic cancer Cancer Research. 79: 883-883. DOI: 10.1158/1538-7445.Am2019-883 |
0.403 |
|
| 2018 |
Cao Y, Chang Q, Cabanero M, Zhang W, Hafezi-Bakhtiari S, Hedley D, Darling G, Quereshy F, Jang R, Elimova E, Knox J, Ornatsky O, Serra S, Chen E. Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. Journal of Gastrointestinal Cancer. PMID 30117091 DOI: 10.1007/S12029-018-0153-9 |
0.385 |
|
| 2018 |
Hosni A, Han K, Le LW, Ringash J, Brierley J, Wong R, Dinniwell R, Brade A, Dawson LA, Cummings BJ, Krzyzanowska MK, Chen EX, Hedley D, Knox J, Easson AM, et al. The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. Oncotarget. 9: 20439-20450. PMID 29755663 DOI: 10.18632/Oncotarget.24926 |
0.332 |
|
| 2017 |
Chiu JW, Krzyzanowska MK, Serra S, Knox JJ, Dhani NC, Mackay H, Hedley D, Moore M, Liu G, Burkes RL, Brezden-Masley C, Roehrl MH, Craddock KJ, Tsao MS, Zhang T, et al. Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer. PMID 29128266 DOI: 10.1016/J.Clcc.2017.10.010 |
0.346 |
|
| 2017 |
Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ. Long term responders to palliative chemotherapy for advanced biliary tract cancer. Journal of Gastrointestinal Oncology. 8: 352-360. PMID 28480074 DOI: 10.21037/Jgo.2017.03.06 |
0.345 |
|
| 2017 |
Matkar PN, Singh KK, Prud’homme G, Hedley D, Leong-Poi H. Abstract 1198: Neuropilin-1 blockade chemosensitizes pancreatic cancer cells via dual inhibition of epithelial-mesenchymal transition and autophagy Cancer Research. 77: 1198-1198. DOI: 10.1158/1538-7445.Am2017-1198 |
0.333 |
|
| 2017 |
Chaudary N, Cheung M, Foltz W, Abdalaty AH, Stewart J, Lindsay P, Siddiqui I, Larsen M, Hill R, Milosevic M, Kim J, Hedley D. Preclinical Development of Targeted Stereotactic Body Radiation Therapy for Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S192. DOI: 10.1016/J.Ijrobp.2017.06.2464 |
0.302 |
|
| 2016 |
Chaudary N, Pintilie M, Hedley D, Hill RP, Milosevic M, Mackay H. Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts. British Journal of Cancer. PMID 27875522 DOI: 10.1038/Bjc.2016.383 |
0.366 |
|
| 2016 |
Goody RB, MacKay H, Pitcher B, Oza A, Siu LL, Kim J, Wong RK, Chen E, Swallow C, Knox J, Kassam Z, Cummings B, Feld R, Hedley D, Liu G, et al. Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 27745984 DOI: 10.1016/J.Ijrobp.2016.08.034 |
0.323 |
|
| 2016 |
Edgar LJ, Vellanki RN, McKee TD, Hedley D, Wouters BG, Nitz M. Isotopologous Organotellurium Probes Reveal Dynamic Hypoxia In Vivo with Cellular Resolution. Angewandte Chemie (International Ed. in English). 55: 13159-13163. PMID 27709819 DOI: 10.1002/Anie.201607483 |
0.342 |
|
| 2016 |
Renouf DJ, Hedley D, Krzyzanowska MK, Schmuck M, Wang L, Moore MJ. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. PMID 27422303 DOI: 10.1007/S00280-016-3102-Y |
0.367 |
|
| 2016 |
Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D. Cytokinetic effects of Wee1 disruption in pancreatic cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 26890070 DOI: 10.1080/15384101.2016.1138188 |
0.385 |
|
| 2016 |
Klinz S, Zheng J, Souza RD, Ventura M, Paz N, Hedley D, Jaffray D, Fitzgerald J. Abstract B47: Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B47 |
0.414 |
|
| 2015 |
Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, et al. A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. PMID 26686201 DOI: 10.1007/S10637-015-0313-8 |
0.394 |
|
| 2015 |
Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. Journal of Controlled Release : Official Journal of the Controlled Release Society. 206: 122-30. PMID 25804872 DOI: 10.1016/J.Jconrel.2015.03.023 |
0.403 |
|
| 2015 |
Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Seminars in Nuclear Medicine. 45: 110-21. PMID 25704384 DOI: 10.1053/J.Semnuclmed.2014.11.002 |
0.426 |
|
| 2015 |
How C, Bruce J, So J, Pintilie M, Haibe-Kains B, Hui A, Clarke B, Hedley D, Hill R, Milosevic M, Fyles A, Yip KW, Liu F. Abstract 5297: Chromosomal instability as a prognostic marker in cervical cancer Cancer Research. 75: 5297-5297. DOI: 10.1158/1538-7445.Am2015-5297 |
0.36 |
|
| 2014 |
Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. British Journal of Cancer. 111: 1132-8. PMID 25072261 DOI: 10.1038/Bjc.2014.418 |
0.321 |
|
| 2014 |
Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. European Journal of Cancer (Oxford, England : 1990). 50: 1909-15. PMID 24857345 DOI: 10.1016/J.Ejca.2014.04.008 |
0.347 |
|
| 2014 |
Lohse I, Lourenco C, Ibrahimov E, Pintilie M, Tsao MS, Hedley DW. Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts. Cancers. 6: 459-71. PMID 24577243 DOI: 10.3390/cancers6010459 |
0.306 |
|
| 2014 |
Youl M, Hashem S, Brade A, Cummings B, Dawson LA, Gallinger S, Hedley D, Jiang H, Kim J, Krzyzanowska MK, Ringash J, Wong R, Brierley J. Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 26: 203-9. PMID 24462333 DOI: 10.1016/J.Clon.2014.01.003 |
0.371 |
|
| 2014 |
Watson M, Chow S, Barsyte D, Arrowsmith C, Shankey TV, Minden M, Hedley D. The study of epigenetic mechanisms based on the analysis of histone modification patterns by flow cytometry. Cytometry. Part a : the Journal of the International Society For Analytical Cytology. 85: 78-87. PMID 24038859 DOI: 10.1002/Cyto.A.22344 |
0.322 |
|
| 2014 |
Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, Laframboise S, Hill RP, Fyles AW. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. International Journal of Cancer. Journal International Du Cancer. 135: 1692-9. PMID 23904154 DOI: 10.1002/Ijc.28403 |
0.311 |
|
| 2014 |
Chiu J, Hotte S, Kollmannsberger C, Renouf D, Cescon D, Hedley D, Chow S, Moscow J, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu L, et al. 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041) European Journal of Cancer. 50: 165-166. DOI: 10.1016/S0959-8049(14)70634-3 |
0.35 |
|
| 2013 |
McNamara MG, Walter T, Horgan AM, Amir E, Cleary S, McKeever EL, Min T, Wallace E, Hedley D, Krzyzanowska M, Moore M, Gallinger S, Greig P, Serra S, Dawson LA, et al. Outcome of Adjuvant Therapy in Biliary Tract Cancers. American Journal of Clinical Oncology. PMID 24572429 DOI: 10.1097/Coc.0B013E31829E19Fb |
0.321 |
|
| 2013 |
Walter T, Horgan AM, McNamara M, McKeeve L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H, Feld R, Moore M, Knox JJ. Response to letter 'outcome of second-line chemotherapy for biliary tract cancer'. European Journal of Cancer (Oxford, England : 1990). 49: 1512-3. PMID 23260192 DOI: 10.1016/J.Ejca.2012.11.025 |
0.314 |
|
| 2013 |
Brandwein JM, Hedley D, Chow S, Yee K, Schuh AC, Gupta V, Schimmer A, Minden MD. A Phase I Study Of Nilotinib As a c-Kit Inhibitor Combined With Re-Induction Chemotherapy For Relapsed and Refractory c-Kit Positive Acute Myeloid Leukemia Blood. 122: 3961-3961. DOI: 10.1182/Blood.V122.21.3961.3961 |
0.312 |
|
| 2013 |
Cescon DW, Bedard PL, Chow S, Chen H, Razak A, Wizemann M, Siu LL, Hedley D. Abstract 4647: Tie2-expressing monocytes (TEMs) as potential biomarkers of angiopoietin-Tie2 (Ang/Tie2) directed therapies: correlative analysis of a phase I study of AMG386 + temsirolimus (T). Cancer Research. 73: 4647-4647. DOI: 10.1158/1538-7445.Am2013-4647 |
0.352 |
|
| 2012 |
Di Valentin T, Alam Y, Ali Alsharm A, Arif S, Aubin F, Biagi J, Booth CM, Bourque S, Burkes R, Champion P, Colwell B, Cripps C, Dallaire M, Dorreen M, Finn N, ... ... Hedley D, et al. Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers. Current Oncology (Toronto, Ont.). 19: 169-74. PMID 22670096 DOI: 10.3747/Co.19.931 |
0.35 |
|
| 2012 |
Chang Q, Hedley D. Emerging applications of flow cytometry in solid tumor biology. Methods (San Diego, Calif.). 57: 359-67. PMID 22503773 DOI: 10.1016/J.Ymeth.2012.03.027 |
0.311 |
|
| 2012 |
Chaudary N, Pintilie M, Hedley D, Fyles AW, Milosevic M, Clarke B, Hill RP, Mackay H. Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation. Cancer. 118: 3105-15. PMID 22028038 DOI: 10.1002/Cncr.26635 |
0.381 |
|
| 2012 |
Renouf DJ, Tang PA, Major P, Krzyzanowska MK, Dhesy-Thind B, Goffin JR, Hedley D, Wang L, Doyle L, Moore MJ. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs. 30: 1203-7. PMID 21526355 DOI: 10.1007/S10637-011-9673-X |
0.368 |
|
| 2012 |
Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, Walde D, Goel R, Southwood B, Gauthier I, Walsh W, McIntosh L, Seymour L. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 30: 779-86. PMID 21170669 DOI: 10.1007/S10637-010-9611-3 |
0.364 |
|
| 2012 |
Ho C, Warkentin A, Beecroft R, Tan K, Walter T, Horgan A, Knox J, Hedley D, Gallinger S, Greig P, Kortan P. Abstract No. 220: Endoscopic or percutaneous biliary drainage for Klatskin tumors? A large retrospective study Journal of Vascular and Interventional Radiology. 23. DOI: 10.1016/J.Jvir.2011.12.270 |
0.312 |
|
| 2011 |
Leighl NB, Shepherd HL, Butow PN, Clarke SJ, McJannett M, Beale PJ, Wilcken NR, Moore MJ, Chen EX, Goldstein D, Horvath L, Knox JJ, Krzyzanowska M, Oza AM, Feld R, ... Hedley D, et al. Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2077-84. PMID 21483008 DOI: 10.1200/Jco.2010.32.0754 |
0.325 |
|
| 2011 |
Chang Q, Jurisica I, Do T, Hedley DW. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer. Cancer Research. 71: 3110-20. PMID 21343390 DOI: 10.1158/0008-5472.Can-10-4049 |
0.334 |
|
| 2010 |
Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia & Lymphoma. 51: 252-60. PMID 20109071 DOI: 10.3109/10428190903585286 |
0.325 |
|
| 2010 |
Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. American Journal of Clinical Oncology. 33: 609-13. PMID 20042973 DOI: 10.1097/Coc.0B013E3181Beac33 |
0.324 |
|
| 2010 |
Yee KW, Chen HT, Brandwein J, Chow S, Sanfelice D, Hedley D, Gupta V, Schimmer A, Sidor CF, Fletcher G, Arnott J, Bray M, Minden MD, Schuh A. A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia Blood. 116: 3307-3307. DOI: 10.1182/Blood.V116.21.3307.3307 |
0.349 |
|
| 2010 |
Sukhai MA, Li X, Hurren R, Wang X, Marko S, Sun H, Gronda M, Seneviratne A, Dissanayake D, Chow S, Bremner R, Hedley D, Minden MD, Pamela O, Schimmer A. The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity Blood. 116: 290-290. DOI: 10.1182/Blood.V116.21.290.290 |
0.341 |
|
| 2010 |
Sukhai MA, Li X, Wang X, Hurren R, Gronda M, Sun J, Chow S, Bremner R, Hedley D, Schimmer AD. Abstract 2529: The anti-malarial agent Mefloquine preferentially demonstrates pre-clinical activity in leukemia and myeloma cells through STAT1-induced reactive oxygen species production Cancer Research. 70: 2529-2529. DOI: 10.1158/1538-7445.Am10-2529 |
0.364 |
|
| 2009 |
Tang P, Gill S, Au HJ, Chen EX, Hedley D, Leroux M, Wang L, Moore MJ. Phase II trial of erlotinib in advanced pancreatic cancer (PC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4609. PMID 27964176 DOI: 10.1200/Jco.2009.27.15_Suppl.4609 |
0.322 |
|
| 2009 |
Moore MJ, Tang P, Renouf D, Major P, Hedley D, Paterson V, Wang L, Dhesy-Thind B, Southwood B, Doyle L. A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15634. PMID 27962741 DOI: 10.1200/Jco.2009.27.15_Suppl.E15634 |
0.354 |
|
| 2009 |
Fyles A, Pintilie M, Hedley D, Bristow R, Wouters B, Hill R, Milosevic M. High interstitial fluid pressure (IFP) and hypoxia as biomarkers of cisplatin chemoradiation response in advanced cervix cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5584. PMID 27962393 DOI: 10.1200/Jco.2009.27.15_Suppl.5584 |
0.357 |
|
| 2009 |
Chow S, Nagai M, He S, Blackman RK, Barsoum J, Vukovic V, Hedley D. Antileukemic Effects of the Novel Agent Elesclomol. Blood. 114: 2736-2736. DOI: 10.1182/Blood.V114.22.2736.2736 |
0.672 |
|
| 2009 |
Brandwein J, Hedley D, Chow S, Schimmer AD, Yee KW, Schuh A, Gupta V, Minden MD. Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia. Blood. 114: 2073-2073. DOI: 10.1182/Blood.V114.22.2073.2073 |
0.335 |
|
| 2009 |
Fyles A, Pintilie M, Hedley D, Bristow R, Hill R, Levin W, Manchul L, Wouters B, Milosevic M. 129 HIGH INTERSTITIAL FLUID PRESSURE (IFP) AND HYPOXIA ARE BIOMARKERS OF CISPLATIN CHEMO-RADIATION RESPONSE IN ADVANCED CERVIX CANCER Radiotherapy and Oncology. 92: S41. DOI: 10.1016/S0167-8140(12)72516-1 |
0.306 |
|
| 2008 |
Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 108: 87-92. PMID 17458693 DOI: 10.1007/S10549-007-9584-X |
0.326 |
|
| 2008 |
Le Tourneau C, Duran I, Chen E, Wang L, Tsao M, Hedley D, Phan N, Do T, Metser U, Siu L. 410 POSTER Phase I pharmacodynamic (PD) and pharmacokinetic (PK) analysis of the sorafenib (S) and erlotinib (E) combination in patients with advanced solid tumors European Journal of Cancer Supplements. 6: 129. DOI: 10.1016/S1359-6349(08)72344-9 |
0.3 |
|
| 2007 |
Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2184-90. PMID 17538163 DOI: 10.1200/Jco.2006.07.6554 |
0.365 |
|
| 2007 |
Zogopoulos G, Rothenmund H, Eppel A, Ash C, Akbari MR, Hedley D, Narod SA, Gallinger S. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Human Genetics. 121: 635-7. PMID 17415588 DOI: 10.1007/S00439-007-0361-Z |
0.311 |
|
| 2007 |
Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, Pond GR, Hedley D, Wong S, Townsley C, Brezden-Masley C, Moore M. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. International Journal of Radiation Oncology, Biology, Physics. 67: 1027-36. PMID 17197132 DOI: 10.1016/J.Ijrobp.2006.10.015 |
0.343 |
|
| 2007 |
Brade AM, Magalhaes J, Siu L, Oza A, Lovell S, de Borja M, Pond G, Sherman I, Hedley D, Chen E. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors Journal of Clinical Oncology. 25: 14030-14030. DOI: 10.1200/Jco.2007.25.18_Suppl.14030 |
0.373 |
|
| 2006 |
Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. British Journal of Cancer. 94: 1136-43. PMID 16570047 DOI: 10.1038/Sj.Bjc.6603055 |
0.374 |
|
| 2006 |
Tong FK, Chow S, Hedley D. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells. Cytometry. Part B, Clinical Cytometry. 70: 107-14. PMID 16498671 DOI: 10.1002/Cyto.B.20092 |
0.373 |
|
| 2006 |
Townsley C, Brade AM, Brezden-Masley C, Hedley D, Gallinger S, Pond GR, Oza AM, Brierley J, Moore MJ. Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer Journal of Clinical Oncology. 24: 4101-4101. DOI: 10.1200/Jco.2006.24.18_Suppl.4101 |
0.331 |
|
| 2006 |
Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, Hansen C, Dancey J, Eisenhauer E. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer--NCIC IND 160 Journal of Clinical Oncology. 24: 3003-3003. DOI: 10.1200/Jco.2006.24.18_Suppl.3003 |
0.371 |
|
| 2006 |
Brade A, Townsley C, Brezden-Masley C, Hedley D, MacLean M, Gallinger S, Pond G, Oza A, Moore M, Brierley J. 63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome Radiotherapy and Oncology. 80: S19. DOI: 10.1016/S0167-8140(06)80804-2 |
0.313 |
|
| 2005 |
Sridhar SS, Stadler W, Le L, Hedley D, Pond G, Wright J, Vokes E, Thomas S, Moore M. Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4677. PMID 27946832 DOI: 10.1200/Jco.2005.23.16_Suppl.4677 |
0.321 |
|
| 2005 |
Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8782-8. PMID 16361566 DOI: 10.1158/1078-0432.Ccr-05-1664 |
0.352 |
|
| 2005 |
Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5526-33. PMID 16061869 DOI: 10.1158/1078-0432.Ccr-05-0081 |
0.407 |
|
| 2005 |
Ringash J, Khaksar SJ, Oza A, Couture J, Japp B, Moore M, Siu LL, Hedley D, Swallow C, Wong S, Cummings B, Kim J, Wong R, Brierley J. Post-operative radiochemotherapy for gastric cancer: adoption and adaptation. Clinical Oncology. 17: 91-95. PMID 15830570 DOI: 10.1016/J.Clon.2004.09.017 |
0.346 |
|
| 2005 |
Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Molecular Cancer Therapeutics. 4: 677-85. PMID 15827342 DOI: 10.1158/1535-7163.Mct-04-0297 |
0.32 |
|
| 2005 |
Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2332-8. PMID 15800324 DOI: 10.1200/Jco.2005.51.008 |
0.379 |
|
| 2004 |
Crump M, Leber B, Kassis J, Hedley D, Minden M, Buckstein R, McIntosh L, Eisenhauer E, Seymour L. A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6611. PMID 28016333 DOI: 10.1200/Jco.2004.22.14_Suppl.6611 |
0.361 |
|
| 2004 |
Mackay H, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao M, Hedley D, Wright J, Oza A. A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3109. PMID 28014849 DOI: 10.1200/Jco.2004.22.90140.3109 |
0.36 |
|
| 2004 |
Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Seminars in Radiation Oncology. 14: 249-58. PMID 15254868 DOI: 10.1016/J.Semradonc.2004.04.006 |
0.355 |
|
| 2004 |
Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience Annals of Oncology. 15: 770-774. PMID 15111345 DOI: 10.1093/Annonc/Mdh172 |
0.36 |
|
| 2004 |
Hedley D, Pintilie M, Woo J, Nicklee T, Morrison A, Birle D, Fyles A, Milosevic M, Hill R. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. The American Journal of Pathology. 164: 557-65. PMID 14742261 DOI: 10.1016/S0002-9440(10)63145-8 |
0.386 |
|
| 2003 |
Nottage M, McLachlan SA, Brittain MA, Oza A, Hedley D, Feld R, Siu LL, Pond G, Moore MJ. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 11: 41-7. PMID 12527953 DOI: 10.1007/S00520-002-0378-8 |
0.322 |
|
| 2003 |
Knox J, Hedley D, Oza A, Siu L, Feld R, Chen E, Nematollahi M, Pond G, Moore M. 191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer European Journal of Cancer Supplements. 1: S60-S61. DOI: 10.1016/S1359-6349(03)90224-2 |
0.341 |
|
| 2002 |
Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Molecular Cancer Therapeutics. 1: 777-83. PMID 12492110 |
0.695 |
|
| 2002 |
Michael M, Hedley D, Oza A, Feld R, Pintilie M, Goel R, Maroun J, Jolivet J, Fields A, Lee IM, Moore MJ. The Palliative Benefit of Irinotecan in 5-Fluorouracil—Refractory Colorectal Cancer: Its Prospective Evaluation by a Multicenter Canadian Trial Clinical Colorectal Cancer. 2: 93-101. PMID 12453323 DOI: 10.3816/Ccc.2002.N.015 |
0.335 |
|
| 2002 |
Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW. Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics. 53: 854-61. PMID 12095550 DOI: 10.1016/S0360-3016(02)02815-8 |
0.646 |
|
| 2002 |
Vukovic V, Nicklee T, Hedley DW. Multiparameter fluorescence mapping of nonprotein sulfhydryl status in relation to blood vessels and hypoxia in cervical carcinoma xenografts. International Journal of Radiation Oncology, Biology, Physics. 52: 837-43. PMID 11849809 DOI: 10.1016/S0360-3016(01)02716-X |
0.639 |
|
| 2002 |
Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer Journal of Clinical Oncology. 20: 680-687. DOI: 10.1200/Jco.20.3.680 |
0.413 |
|
| 2001 |
Vukovic V, Haugland HK, Nicklee T, Morrison AJ, Hedley DW. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Research. 61: 7394-8. PMID 11606368 |
0.635 |
|
| 2001 |
Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3269-75. PMID 11595724 |
0.698 |
|
| 2001 |
Constantinou P, Vukovic V, Haugland HK, Nicklee T, Hedley DW, Wilson BC. Imaging of whole tumor cut sections using a novel scanning beam confocal fluorescence MACROscope. Journal of Biomedical Optics. 6: 326-31. PMID 11516323 DOI: 10.1117/1.1383779 |
0.646 |
|
| 2001 |
Vukovic V, Nicklee T, Hedley DW. Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 60: 69-73. PMID 11410306 DOI: 10.1016/S0167-8140(01)00331-0 |
0.656 |
|
| 2001 |
Muzzammil T, Moore MJ, Hedley D, Ballinger JR. Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. British Journal of Cancer. 84: 367-73. PMID 11161402 DOI: 10.1054/Bjoc.2000.1621 |
0.318 |
|
| 2001 |
Brierley J, Oza A, Wong C, Ringash J, Catton P, Siu L, Hedley D, Feld R, MacLean M, Moore M. Phase I/II study of combined modality therapy in pancreatic cancer with gemcitabine (Gem) and escalating dose radiation therapy (RT) International Journal of Radiation Oncology*Biology*Physics. 51: 271-272. DOI: 10.1016/S0360-3016(01)02322-7 |
0.315 |
|
| 2000 |
Vukovic V, Pheng SR, Stewart A, Vik CH, Hedley DW. Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein. International Journal of Radiation Biology. 76: 757-62. PMID 10902729 DOI: 10.1080/09553000050028904 |
0.59 |
|
| 2000 |
Vukovic V, Nicklee T, Hedley DW. Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 1826-32. PMID 10815904 |
0.663 |
|
| 1999 |
Kavanagh MC, Tsang V, Chow S, Koch C, Hedley D, Minkin S, Hill RP. A comparison in individual murine tumors of techniques for measuring oxygen levels. International Journal of Radiation Oncology, Biology, Physics. 44: 1137-46. PMID 10421548 DOI: 10.1016/S0360-3016(99)00104-2 |
0.3 |
|
| 1999 |
Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 13: 343-7. PMID 10086724 DOI: 10.1038/Sj.Leu.2401308 |
0.321 |
|
| 1998 |
De Jaeger K, Merlo FM, Kavanagh MC, Fyles AW, Hedley D, Hill RP. Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. International Journal of Radiation Oncology, Biology, Physics. 42: 717-21. PMID 9845083 DOI: 10.1016/S0360-3016(98)00323-X |
0.338 |
|
| 1998 |
Moore MJ, Feld R, Hedley D, Oza A, Siu LL. A phase II study of temozolomide in advanced untreated pancreatic cancer. Investigational New Drugs. 16: 77-79. PMID 9740547 DOI: 10.1023/A:1006043332368 |
0.395 |
|
| 1996 |
Chow S, Hedley D. Flow cytometric determination of glutathione in clinical samples. Cytometry. 21: 68-71. PMID 8529474 DOI: 10.1002/Cyto.990210113 |
0.397 |
|
| 1995 |
Hedley D, Chow S. Glutathione and cellular resistance to anti-cancer drugs. Methods in Cell Biology. 31-44. PMID 7533246 DOI: 10.1016/S0091-679X(08)61066-3 |
0.325 |
|
| 1985 |
Stuart-Harris R, Fox RM, Raghavan D, Coates AS, Hedley D, Levi JA, Woods RL, Tattersall MHN. Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer. Thorax. 40: 346-350. PMID 2410994 DOI: 10.1136/Thx.40.5.346 |
0.35 |
|
| 1984 |
Coates AS, Tattersall MH, Swanson C, Hedley D, Fox RM, Raghavan D. Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. Journal of Clinical Oncology. 2: 756-761. PMID 6376719 DOI: 10.1200/Jco.1984.2.7.756 |
0.39 |
|
| 1984 |
Hedley D, Dalgleish A, Raghavan D, Tattersall MHN, Coates A, Fox R. Advanced Breast Cancer: Response To High Dose Oral Medroxyprogesterone Acetate Australian and New Zealand Journal of Medicine. 14: 251-254. PMID 6238589 DOI: 10.1111/J.1445-5994.1984.Tb03761.X |
0.337 |
|
| 1983 |
Friedlander ML, Kearsley JH, Sims K, Coates A, Hedley D, Raghavan D, Fox RM, Tattersall MH. Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy Australian and New Zealand Journal of Medicine. 13: 53-56. PMID 6136266 DOI: 10.1111/J.1445-5994.1983.Tb04550.X |
0.319 |
|
| Show low-probability matches. |